Challenges and progress related to gene editing in rare skin diseases

Josefina Piñón Hofbauer,Christina Guttmann-Gruber,Verena Wally,Anshu Sharma,Iris K Gratz,Ulrich Koller,Iris K. Gratz

DOI: https://doi.org/10.1016/j.addr.2024.115294

IF: 16.1

2024-05-01

Advanced Drug Delivery Reviews

Abstract:Genodermatoses represent a large group of inherited skin disorders encompassing clinically-heterogeneous conditions that manifest in the skin and other organs. Depending on disease variant, associated clinical manifestations and secondary complications can severely impact patients' quality of life and currently available treatments are transient and not curative. Multiple emerging approaches using CRISPR-based technologies offer promising prospects for therapy. Here, we explore current advances and challenges related to gene editing in rare skin diseases, including different strategies tailored to mutation type and structural organization of the affected gene, considerations for in vivo and ex vivo applications, the critical issue of delivery into the skin, and immune aspects of therapy. Against the backdrop of a landmark FDA approval for the first re-dosable gene replacement therapy for a rare genetic skin disorder, gene editing approaches are inching closer to the clinics and the possibility of a local permanent cure for patients affected by these disorders.

pharmacology & pharmacy